Meeting
2021 ASCO Annual Meeting
Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).
Authors
Hyun Ae Jung
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
Hyun Ae Jung , Yeong Jeong Jeon , Jhingook Kim , Sehhoon Park , Jong-Mu Sun , Se-Hoon Lee , Jin Seok Ahn , Myung-Ju Ahn , Keunchil Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8529)
DOI
10.1200/JCO.2021.39.15_suppl.8529
Abstract #
8529
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical and financial implications of ADUARA trial on a real-world population.
First Author: Bharathi Muthusamy
Poster
2015 ASCO Annual Meeting
The impact of a Bim deletion polymorphism on the survival of patients with completely resected non-small cell lung cancer.
First Author: Jun Atsumi
Poster
2014 ASCO Annual Meeting
SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.
First Author: Nathan A. Pennell
Poster
2011 ASCO Annual Meeting
Mutations of EGFR, K-ras, and EML-4ALK genes in resected lung adenocarcinoma and their clinical significance.
First Author: T. Ohba